Novartis India (BOM:500672) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500672 Novartis India Ltd BOM:500672
54 GF Score
Price ₹2,393.15
GF Value ₹1,040.54
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novartis India Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

BOM:500672
54GF Score
Novartis India Ltd BOM:500672
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novartis India (BOM:500672) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹2,393.15 is trading 130% above its estimated GF Value™ of ₹1,040.54. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for BOM:500672:

  • Interest Received:
  • GF Value™: ₹1,040.54 vs. price of ₹2,393.15 (130% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis India Business Description

Other Exchanges NOVARTIND:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
54GF Score

Get the complete analysis for BOM:500672

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,393.15
Price
₹1,040.54
GF Value